What question did this study set out to answer?

To compare the ablative efficacy and safety of intravesical thiotepa versus mitomycin C in patients with residual Ta, T1, and TIS transitional cell carcinoma of the bladder.

December 1, 1988The Journal of Urology

Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

View Full Paper

Ask AI

Bookmark

To compare the ablative efficacy and safety of intravesical thiotepa versus mitomycin C in patients with residual Ta, T1, and TIS transitional cell carcinoma of the bladder.
Conducted a multicenter, prospective randomized phase III trial by the National Bladder Cancer Group evaluating patients with residual Ta, T1, or TIS bladder cancer (N=149; 73 thiotepa, 76 mitomycin C).
Administered eight weekly intravesical instillations of either thiotepa or mitomycin C, followed by response evaluation with cystoscopy and biopsy or cytology 4 weeks post-treatment.
Complete response rates were 26% (19/73) in the thiotepa arm versus 39% (30/76) in the mitomycin C arm (p=0.08), with mitomycin C showing superiority primarily in the Ta subgroup.
Overall response rates (complete plus partial) were 53% for thiotepa versus 63% for mitomycin C (p=0.23), while carcinoma in situ (TIS) demonstrated similar response between arms.
Adverse events differed by agent: urinary frequency occurred in 30.1% (22/73) of thiotepa vs 40.8% (31/76) of mitomycin C patients, rash in 2.7% (2/73) vs 18.4% (14/76), and bone marrow depression in 20.5% (15/73) vs 15.8% (12/76).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates higher tumor response rates with mitomycin C versus thiotepa in superficial bladder cancer, suggesting modest benefits with distinct toxicity profiles.

Cite This Study

Heney et al. (1988) studied this question.

synapsesocial.com/papers/6a971db518aea7995cf6ad4e https://doi.org/10.1016/s0022-5347(17)42052-0

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates higher tumor response rates with mitomycin C versus thiotepa in superficial bladder cancer, suggesting modest benefits with distinct toxicity profiles.

Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

Key Points

Discussion

Implication

Cite This Study

Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider